Pneumococcal (vaccine)
Sponsors
GlaxoSmithKline
Conditions
Acellular PertussisDiphtheriaHaemophilus Influenzae Type bHepatitis AHepatitis BInfections, StreptococcalPoliomyelitisProphylaxis Pneumococcal Vaccine
Phase 2
A Study in Children With Different Formulations of GSK Biologicals' 11 Valent Pneumococcal Conjugate Vaccine
CompletedNCT00169481
Start: 2004-10-31End: 2005-05-31Updated: 2017-01-10
Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine or a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children Aged 11-18 Mths, Previously Vaccinated in Study 103488
CompletedNCT00307567
Start: 2005-11-30End: 2006-03-31Target: 689Updated: 2016-09-23
Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine.
CompletedNCT00338351
Start: 2006-04-30End: 2006-10-31Target: 240Updated: 2016-09-28
Phase 3
Study of Immunological Memory Induced in Children by a Full 4 Dose Vaccination Schedule of 11 Valent Pneumococcal Conjugate Vaccine by Giving 1 Dose of Aventis Pasteur's 23-valent Pneumococcal Polysaccharide Vaccine (Pneumo 23)
CompletedNCT00169507
Start: 2005-03-31End: 2005-04-30Target: 100Updated: 2017-05-30
A Lot-to-lot Consistency (3 Lots of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine) & Non-inferiority Study
CompletedNCT00307554
Start: 2005-11-30End: 2006-06-30Target: 1600Updated: 2016-09-26
Assess the Immunogenicity of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine
CompletedNCT00307541
Start: 2005-10-27End: 2006-04-07Target: 120Updated: 2020-01-02
Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine.
CompletedNCT00334334
Start: 2006-06-30End: 2007-08-31Updated: 2016-11-04